
Beyond Humira: What’s Driving Drug Spend Now?
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
By:
About this listen
The Vizient Summer 2025 Spend Management Outlook (SMO) provides an integrated perspective on trends, factors and future expenses providers will face across the various dimensions of healthcare. In this episode, Dr. Carina Dolan and Dr. Jeni Hayes join host Carolyn Liptak to discuss pharmacy insights from the SMO including declining drug price inflation and how autoimmune conditions have surpassed oncology in total pharmacy costs. They also touch on pediatric spend drivers, biosimilar competition, and the impact of novel therapies. Tune in to VerifiedRx for practical insights to help pharmacy leaders plan for what’s ahead.
Guest speakers:
Carina Dolan, Pharm. D., MS Pharm, BCOP Associate Vice President, Clinical Oncology, Pharmacoeconomics and Market Insights Vizient Jeni Hayes, PharmD, MS Pharm, BCPS Senior Clinical Manager, Market Intelligence Vizient Host: Carolyn Liptak, BS Pharm, MBA VerifiedRx Host
Show Notes:
[01:13-02:41] Key pharmacy trends emerging from the Summer SMO
[02:42-04:00] Current pharmacy trends
[04:01-05:55] Pharmacy spend for autoimmune conditions has exceeded that of oncology
[05:56-07:36] Key takeaways
[07:37-08:47] Significant trends in this latest therapeutic insights update
[08:48-10:04] Challenges in gene and cell therapy space
[10:05-11:33] The Therapeutic Insights webpage for pediatrics
[11:34-13:41] Other reflections from the SMO
[13:42-14:49] How to locate the SMO
Links | Resources:
Vizient Spend Management Outlook
Vizient Therapeutic class insights
VerifiedRx Listener Feedback Survey:
We would love to hear from you - Please click here
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Spotify
Android
RSS Feed